Evidence map›Paper›PMID 33073032›Full record

ReviewInternational journal of neonatal screening2020

Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic Fibrosis.

Rachael E Armstrong, Lucy Frith, Fiona M Ulph, Kevin W Southern

Open access · goldAbstract readReview
In one paragraph

Review in International journal of neonatal screening, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Why Do We Screen Newborn Infants for Cystic Fibrosis?International journal of neonatal screening · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rachael E ArmstrongDepartment of Women's and Children's Health, University of Liverpool, Liverpool L12 2AP, UK; r.armstrong3@doctors.org.uk.
Lucy FrithInstitute of Population Health, University of Liverpool, Liverpool L69 3GL, UK; frith@liverpool.ac.uk.
Fiona M UlphDivision of Psychology & Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PL, UK; Fiona.Ulph@manchester.ac.uk.ORCID 0000-0003-3590-6542
Kevin W SouthernDepartment of Women's and Children's Health, University of Liverpool, Liverpool L12 2AP, UK; r.armstrong3@doctors.org.uk.
University of Liverpool · GBManchester Academic Health Science Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newborn bloodspot screening for cystic fibrosis is a valid public health strategy for populations with a high incidence of this inherited condition. There are a wide variety of approaches to screening and in this paper, we propose that a bioethical framework is required to determine the most appropriate screening protocol for a population. This framework depends on the detailed evaluation of the ethical consequences of all screening outcomes and placing these in the context of the genetic profile of the population screened, the geography of the region and the healthcare resources available.

Indexed as

bioethicscystic fibrosiscystic fibrosis screen positiveinconclusive diagnosis (CFSPID)newborn bloodspot screening

Identifiers

PMID33073032
PMCPMC7422997
OpenAlexW3031246835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.